Relmada Therapeutics Stock Pattern Recognition Upside Gap Two Crows

RLMD Stock  USD 0.47  0.01  2.08%   
Relmada Therapeutics pattern recognition tool provides the execution environment for running the Upside Gap Two Crows recognition and other technical functions against Relmada Therapeutics. Relmada Therapeutics value trend is the prevailing direction of the price over some defined period of time. The concept of trend is an important idea in technical analysis, including the analysis of pattern recognition indicators. As with most other technical indicators, the Upside Gap Two Crows recognition function is designed to identify and follow existing trends. Relmada Therapeutics momentum indicators are usually used to generate trading rules based on assumptions that Relmada Therapeutics trends in prices tend to continue for long periods.

Recognition
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was twelve with a total number of output elements of fourty-nine. The function did not return any valid pattern recognition events for the selected time horizon. The Upside Gap Two Crows pattern suggests that Relmada Therapeutics investor sentiment is turning from bullish to bearish.

Relmada Therapeutics Technical Analysis Modules

Most technical analysis of Relmada Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Relmada from various momentum indicators to cycle indicators. When you analyze Relmada charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Relmada Therapeutics Predictive Technical Analysis

Predictive technical analysis modules help investors to analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Relmada Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Relmada Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Relmada Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Relmada Therapeutics's daily price indicators and compare them against related drivers, such as pattern recognition and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Relmada Therapeutics's intrinsic value. In addition to deriving basic predictive indicators for Relmada Therapeutics, we also check how macroeconomic factors affect Relmada Therapeutics price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
 2019 2021 2023 2024 (projected)
Payables Turnover4.5E-41.12E-41.29E-41.23E-4
Days Of Inventory On Hand87.9K3.3M3.0M3.1M
Hype
Prediction
LowEstimatedHigh
0.030.5211.49
Details
Intrinsic
Valuation
LowRealHigh
0.152.9413.91
Details
3 Analysts
Consensus
LowTargetHigh
9.4510.3811.52
Details
Earnings
Estimates (0)
LowProjected EPSHigh
0.000.000.00
Details

Become your own money manager

As an individual investor, you need to find a reliable way to track all your investment portfolios' performance accurately. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing you full analytical transparency into your positions, our tools can tell you how much better you can do without increasing your risk or reducing expected return.

Did you try this?

Run Options Analysis Now

   

Options Analysis

Analyze and evaluate options and option chains as a potential hedge for your portfolios
All  Next Launch Module

Trending Themes

If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.
Momentum Idea
Momentum
Invested over 40 shares
Dividend Beast Idea
Dividend Beast
Invested over 50 shares
Warren Buffett Holdings Idea
Warren Buffett Holdings
Invested few shares
Investor Favorites Idea
Investor Favorites
Invested over 40 shares
Social Domain Idea
Social Domain
Invested few shares
Impulse Idea
Impulse
Invested few shares
Macroaxis Index Idea
Macroaxis Index
Invested few shares
Millennials Best Idea
Millennials Best
Invested few shares
Electronic Equipment Idea
Electronic Equipment
Invested few shares
Investing Idea
Investing
Invested few shares
When determining whether Relmada Therapeutics is a strong investment it is important to analyze Relmada Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Relmada Therapeutics' future performance. For an informed investment choice regarding Relmada Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Relmada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Relmada Therapeutics. If investors know Relmada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Relmada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.86)
Return On Assets
(0.59)
Return On Equity
(1.00)
The market value of Relmada Therapeutics is measured differently than its book value, which is the value of Relmada that is recorded on the company's balance sheet. Investors also form their own opinion of Relmada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Relmada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Relmada Therapeutics' market value can be influenced by many factors that don't directly affect Relmada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Relmada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Relmada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Relmada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.